Drugs Made In America Acquisition II (NASDAQ:DMII) Posts Earnings Results

Drugs Made In America Acquisition II (NASDAQ:DMII – Get Free Report) posted its quarterly earnings results on Monday. The company reported $0.07 earnings per share for the quarter, FiscalAI reports.

Drugs Made In America Acquisition II Stock Performance

DMII opened at $10.23 on Wednesday. The business has a fifty day simple moving average of $10.19 and a 200 day simple moving average of $10.08. Drugs Made In America Acquisition II has a 1 year low of $9.86 and a 1 year high of $10.33.

Wall Street Analyst Weigh In

Several research firms have commented on DMII. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a report on Tuesday, September 1st. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II to a “hold” rating in a research note on Saturday, October 24th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, Drugs Made In America Acquisition II presently has an average rating of “Sell”.

Read Our Latest Stock Analysis on Drugs Made In America Acquisition II

Institutional Investors Weigh In On Drugs Made In America Acquisition II

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Glazer Capital LLC bought a new position in Drugs Made In America Acquisition II during the 3rd quarter worth $23,818,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Drugs Made In America Acquisition II during the 1st quarter worth $19,960,000. First Trust Capital Management L.P. acquired a new stake in shares of Drugs Made In America Acquisition II during the 3rd quarter worth $13,218,000. Sona Asset Management US LLC grew its holdings in shares of Drugs Made In America Acquisition II by 66.7% during the 1st quarter. Sona Asset Management US LLC now owns 500,000 shares of the company’s stock worth $4,985,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Wealthspring Capital LLC bought a new position in shares of Drugs Made In America Acquisition II in the third quarter worth $4,063,000.

Drugs Made In America Acquisition II Company Profile

(Get Free Report)

Drugs Made In America Acquisition II is a special purpose acquisition company, or SPAC. It was formed to pursue a merger, acquisition or similar business combination with an operating company. The company has identified the pharmaceutical sector as its area of focus, with an emphasis on businesses connected to the production of drugs in the United States. It does not operate a drug-manufacturing or pharmaceutical business of its own.

Read More

Receive News & Ratings for Drugs Made In America Acquisition II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition II and related companies with MarketBeat.com's FREE daily email newsletter.